Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy: A GRASP-LGMD Study

Overview

Journal Res Sq

Date 2023 Oct 27

PMID 37886601

Authors

Amy Doody

Lindsay Alfano

Jordi Diaz-Manera

Linda Lowes

Tahseen Mozaffar

Kathy Mathews

Conrad C Weihl

Matthew Wicklund

Jeffery Statland

Nicholas E Johnson

Affiliations

Soon will be listed here.

Abstract

Background: The Limb Girdle Muscular Dystrophies (LGMDs) are characterized by progressive weakness of the shoulder and hip girdle muscles as a result of over 30 different genetic mutations. This study is designed to develop clinical outcome assessments across the group of disorders.

Methods/design: The primary goal of this study is to evaluate the utility of a set of outcome measures on a wide range of LGMD phenotypes and ability levels to determine if it would be possible to use similar outcomes between individuals with different phenotypes. We will perform a multi-center, 12-month study of 188 LGMD patients within the established Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP-LGMD) Research Consortium, which is comprised of 11 sites in the United States and 2 sites in Europe. Enrolled patients will be clinically affected and have mutations in CAPN3 (LGMDR1), ANO5 (LGMDR12), DYSF (LGMDR2), DNAJB6 (LGMDD1), SGCA (LGMDR3), SGCB (LGMDR4), SGCD (LGMDR6), or SGCG (LGMDR5, or FKRP-related (LGMDR9).

Discussion: To the best of our knowledge, this will be the largest consortium organized to prospectively validate clinical outcome assessments (COAs) in LGMD at its completion. These assessments will help clinical trial readiness by identifying reliable, valid, and responsive outcome measures as well as providing data driven clinical trial decision making for future clinical trials on therapeutic agents for LGMD. The results of this study will permit more efficient clinical trial design. All relevant data will be made available for investigators or companies involved in LGMD therapeutic development upon conclusion of this study as applicable.

Trial Registration: clinicaltrials.gov NCT03981289; Date of registration: 6/10/2019.

References

Xu L, Lu P, Wang C, Keramaris E, Qiao C, Xiao B . Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions. Mol Ther. 2013; 21(10):1832-40. PMC: 3808132. DOI: 10.1038/mt.2013.156. View

Fayssoil A, Ogna A, Chaffaut C, Chevret S, Guimaraes-Costa R, Leturcq F . Natural History of Cardiac and Respiratory Involvement, Prognosis and Predictive Factors for Long-Term Survival in Adult Patients with Limb Girdle Muscular Dystrophies Type 2C and 2D. PLoS One. 2016; 11(4):e0153095. PMC: 4847860. DOI: 10.1371/journal.pone.0153095. View

Pozsgai E, Griffin D, Heller K, Mendell J, Rodino-Klapac L . Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice. Mol Ther. 2017; 25(4):855-869. PMC: 5383645. DOI: 10.1016/j.ymthe.2017.02.013. View

Mendell J, Al-Zaidy S, Shell R, Arnold W, Rodino-Klapac L, Prior T . Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017; 377(18):1713-1722. DOI: 10.1056/NEJMoa1706198. View

Finkel R, Mercuri E, Darras B, Connolly A, Kuntz N, Kirschner J . Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017; 377(18):1723-1732. DOI: 10.1056/NEJMoa1702752. View

Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi G . Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014; 50(4):477-87. PMC: 4241581. DOI: 10.1002/mus.24332. View

Verdu-Diaz J, Alonso-Perez J, Nunez-Peralta C, Tasca G, Vissing J, Straub V . Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. Neurology. 2020; 94(10):e1094-e1102. DOI: 10.1212/WNL.0000000000009068. View

James M, Rose K, Alfano L, Reash N, Eagle M, Lowes L . Remote Delivery of Motor Function Assessment and Training for Clinical Trials in Neuromuscular Disease: A Response to the COVID-19 Global Pandemic. Front Genet. 2021; 12:735538. PMC: 8592083. DOI: 10.3389/fgene.2021.735538. View

Alfano L, Miller N, Berry K, Yin H, Rolf K, Flanigan K . The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017; 27(5):452-457. DOI: 10.1016/j.nmd.2017.02.007. View

10.

Kierkegaard M, Tollback A . Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord. 2007; 17(11-12):943-9. DOI: 10.1016/j.nmd.2007.08.003. View

11.

Angelini C . LGMD. Identification, description and classification. Acta Myol. 2021; 39(4):207-217. PMC: 7783424. DOI: 10.36185/2532-1900-024. View

12.

Zaidman C, Proud C, McDonald C, Lehman K, Goedeker N, Mason S . Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023; 94(5):955-968. DOI: 10.1002/ana.26755. View

13.

Moore U, Caldas de Almeida Araujo E, Reyngoudt H, Gordish-Dressman H, Smith F, Wilson I . Water T2 could predict functional decline in patients with dysferlinopathy. J Cachexia Sarcopenia Muscle. 2022; 13(6):2888-2897. PMC: 9745487. DOI: 10.1002/jcsm.13063. View

14.

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

15.

Mercuri E, Darras B, Chiriboga C, Day J, Campbell C, Connolly A . Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018; 378(7):625-635. DOI: 10.1056/NEJMoa1710504. View

16.

Harris E, Bladen C, Mayhew A, James M, Bettinson K, Moore U . The Clinical Outcome Study for dysferlinopathy: An international multicenter study. Neurol Genet. 2016; 2(4):e89. PMC: 4994875. DOI: 10.1212/NXG.0000000000000089. View

17.

Nallamilli B, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T . Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. 2018; 5(12):1574-1587. PMC: 6292381. DOI: 10.1002/acn3.649. View

18.

Bengoechea R, Pittman S, Tuck E, True H, Weihl C . Myofibrillar disruption and RNA-binding protein aggregation in a mouse model of limb-girdle muscular dystrophy 1D. Hum Mol Genet. 2015; 24(23):6588-602. PMC: 4634370. DOI: 10.1093/hmg/ddv363. View

19.

Willis T, Hollingsworth K, Coombs A, Sveen M, Andersen S, Stojkovic T . Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One. 2013; 8(8):e70993. PMC: 3743890. DOI: 10.1371/journal.pone.0070993. View

20.

JEBSEN R, Taylor N, Trieschmann R, Trotter M, Howard L . An objective and standardized test of hand function. Arch Phys Med Rehabil. 1969; 50(6):311-9. View